Search

Your search keyword '"Gross, Andrea M."' showing total 7 results
Start Over Author "Gross, Andrea M." Publisher lippincott williams & wilkins
7 results on '"Gross, Andrea M."'

1. Consensus-Based Best Practice Guidelines for the Management of Spinal Deformity and Associated Tumors in Pediatric Neurofibromatosis Type 1: Screening and Surveillance, Surgical Intervention, and Medical Therapy.

Author

Xu, Amy L., Suresh, Krishna V., Gomez, Jaime A., Emans, John B., Larson, A. Noelle, Cahill, Patrick J., Andras, Lindsay M., White, Klane K., Miller, Daniel J., Murphy, Joshua S., Groves, Mari L., Belzberg, Allan J., Hwang, Steven W., Rosser, Tena L., Staedtke, Verena, Ullrich, Nicole J., Sato, Aimee A., Blakeley, Jaishri O., Schorry, Elizabeth K., and Gross, Andrea M.

Published
2023
Full Text
View/download PDF

2. Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.

Author

Akshintala, Srivandana, Khalil, Nashwa, Yohay, Kaleb, Muzikansky, Alona, Allen, Jeffrey, Yaffe, Anna, Gross, Andrea M., Fisher, Michael J., Blakeley, Jaishri O., Oberlander, Beverly, Pudel, Miriam, Engelson, Celia, Obletz, Jaime, Mitchell, Carole, Widemann, Brigitte C., Stevenson, David A., Plotkin, Scott R., and REiNS International Collaboration

Published
2021
Full Text
View/download PDF

7. Are Some Randomized Clinical Trials Impossible?

Author

Rios JJ, Richards BS, Stevenson DA, Oberlander B, Viskochil D, Gross AM, Dombi E, Widemann BC, Plotkin SR, May CJ, Ullrich NJ, Goldstein RY, Jain V, and Schorry EK

Subjects
Bone Morphogenetic Proteins pharmacology, Humans, Neurofibromatosis 1 complications, Rare Diseases, Recombinant Proteins pharmacology, Sample Size, Tibia abnormalities, Tibia surgery, Bone Morphogenetic Protein 2 pharmacology, Neurofibromatosis 1 surgery, Orthopedic Procedures methods, Patient Selection, Pseudarthrosis congenital, Pseudarthrosis surgery, Randomized Controlled Trials as Topic methods, Transforming Growth Factor beta pharmacology
Abstract

Congenital tibial pseudarthrosis is a rare condition seen in neurofibromatosis type 1 (NF1), and treatment is complex. A randomized, placebo-controlled trial of bone morphogenetic protein (rhBMP-2; INFUSE bone graft) at time of tibial surgery was developed by the Neurofibromatosis Clinical Trials Consortium. Patients were randomized to receive rhBMP-2 that would, or would not, be added to the standard surgical procedure consisting of resection of pseudarthrosis tissue, insertion of a rigid intramedullary rod, and placement of autogenous iliac crest bone graft. Despite involvement of 16 centers with wide experience with NF1 orthopaedic management, only 5 patients (of 54 required) were able to be enrolled in the study during a 3-year time period. Because of the inability to recruit sufficient patients, this study was closed in June 2019, with plans to terminate. The obstacles that were encountered during the study are summarized. The authors question whether a randomized, placebo-controlled trial of a rare pediatric orthopaedic condition is possible to accomplish. Recommendations are provided to guide future studies of orthopaedic manifestations of NF1.Level of Evidence: Level V.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results